NovaBay: Tomorrow's Staple In Antimicrobial Therapy?

By Smith On Stocks: Investment Thesis

By Len Zehr:With the launch of a global pivotal trial, NovaBay Pharmaceuticals (NBY) has achieved a major development milestone in its efforts to commercialize an eye drop for the treatment of adenoviral conjunctivitis with its anti-infective aganocide, NVC-422.Dr. David Stroman

By Len Zehr:NovaBay Pharmaceuticals (NBY) says key study data demonstrating that development of resistance to its lead Aganocide compound, NVC-422, is highly unlikely for a variety of infectious organisms, including methicillin-resistant S. aureus (MRSA), compared with traditional antibiotics, were published in the May 2012 issue of Antimicrobial Agents and Chemotherapy, the journal for the American Society for Microbiology.

By David Sobek:Novabay (NBY) is developing a novel anti-microbial agent (NVC-422) that has a mechanism of action different than current antibiotics as it is derived from a very different source. The drug has shown some early efficacy signals in a number of topical indications: impetigo, viral conjunctivitis, and catheter associated urinary tract infection.

By Len Zehr:NovaBay Pharmaceuticals (NBY) is taking a less risky road developing its lead Aganocide compound to mimic the body's natural defenses against infections from pink eye, urinary catheter blockage and encrustation (UCBE) and against a highly contagious skin infection called impetigo. Dr. Ron Najafi

By Timeless Wealth:Prescribing medication that has no toll on a patient’s ailment burdens our healthcare system – and to those inherently concerned with what that means: it costs you more for less in return. The antibiotics that treated microbial infections for generations have led to mutation of bacteria, and ultimately, resistance to common treatment.

By Smith On Stocks: Introduction

BySteven Barnes: Novabay Pharmaceuticals has good news that could boost its value.